Table 1.
Baseline characteristics of the trial participants (n = 85), according to vaccination schedule assigned (rAd26/ChAdOx1, rAd26/BBIBP-CorV or rAd26/rAd5).
| Characteristic | Vaccine schedule |
||
|---|---|---|---|
| rAd26/ChAdOx1 (n = 27) | rAd26/BBIBP-CorV (n = 27) | rAd26/rAd5 (n = 31) | |
| Mean age [years (SD)] | 68 (3) | 68 (3) | 69 (3) |
| Body mass Index [kg/m2 (SD)] | 29.22 (4.99) | 27.49 (3.59) | 28.43 (5.41) |
| Days since first vaccination [days (range)] | 76 (64–89) | 74 (58–88) | 71 (38–87) |
| Sex female [n (%)] | 16 (59) | 16 (59) | 17 (55) |
| Coexisting condition [n (%)] | |||
| Diabetes mellitus | 6 (22) | 4 (15) | 3 (10) |
| COPD | 1 (4) | 1 (4) | 2 (6) |
| Cardiovascular disease | 13 (48) | 15 (56) | 14 (45) |
SD: Standard deviation. COPD: Chronic obstructive pulmonary disease.